Michael J. Sofia | Academic Influence

Michael J. Sofia's AcademicInfluence.com Rankings

Michael J. Sofia

Chemistry

#1172

World Rank

#1834

Historical Rank

#467

USA Rank

Organic Chemistry

#250

World Rank

#308

Historical Rank

#71

USA Rank

chemistry Degrees

Download Badge

Chemistry

Michael J. Sofia's Degrees

PhD Chemistry University of California, Berkeley
Bachelors Chemistry University of California, Berkeley

Why Is Michael J. Sofia Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael J. Sofia is a chemist whose main research focus is hepatitis C virus and hepatitis B virus drug discovery. He was a co-recipient of the Lasker-DeBakey Clinical Medical Research Award for his work on hepatitis C in 2016 and of the Gertrude B. Elion Memorial Award from the International Society for Antiviral Research in 2017.

(See a Problem?)

Michael J. Sofia's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. (2010) (526)
Structural basis for RNA replication by the hepatitis C virus polymerase (2015) (271)
Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 (2010) (250)
Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. (2012) (245)
PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication (2010) (141)
Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA (2012) (122)
Synthesis of diastereomerically pure nucleotide phosphoramidates. (2011) (109)
Haloenol lactones. Potent enzyme-activated irreversible inhibitors for alpha-chymotrypsin. (1983) (98)
Stereospecific reductive methylation via a radical cyclization-desilylation process (1986) (79)
Carbohydrate-Based Small-Molecule Scaffolds for the Construction of Universal Pharmacophore Mapping Libraries (1998) (77)
An Empirical Process for the Design of High-Throughput Screening Deck Filters (2006) (75)
An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. (2009) (74)
Stereospecific Solution- and Solid-Phase Glycosylations. Synthesis of β-Linked Saccharides and Construction of Disaccharide Libraries Using Phenylsulfenyl 2-Deoxy-2-Trifluoroacetamido Glycopyranosides as Glycosyl Donors1 (1999) (71)
Nucleotide Prodrugs for HCV Therapy (2011) (67)
Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase. (2000) (62)
The first potent inhibitor of squalene synthase : a profound contribution of an ether oxygen to inhibitor-enzyme interaction (1991) (60)
Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY293111: in vivo pulmonary studies (2000) (55)
Discovery of novel disaccharide antibacterial agents using a combinatorial library approach. (1999) (53)
2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. (2010) (53)
Simple and Efficient Method for the Oxidation of Sulfides to Sulfoxides: Application to the Preparation of Glycosyl Sulfoxides. (1996) (47)
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? (2014) (44)
Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. (2011) (43)
Nucleotide prodrugs for the treatment of HCV infection. (2013) (43)
Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection. (2011) (43)
Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis. (2012) (42)
Inhibition of hepatitis C virus NS5A by fluoro-olefin based γ-turn mimetics. (2012) (42)
Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. (2014) (41)
Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. (1990) (41)
Efficient synthesis of a stereochemically defined carbohydrate scaffold: carboxymethyl 2-acetamido-6-azido-4-O-benzyl-2-deoxy-alpha-D-glucopyranoside. (2000) (41)
Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation (2018) (38)
Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs. (2011) (37)
Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-d-2′-Deoxy-2′-α-Fluoro-2′-β-C-Methylguanosine (2011) (36)
Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients (2020) (34)
Stereoselective synthesis of PSI-352938: a β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyl-3',5'-cyclic phosphate nucleotide prodrug for the treatment of HCV. (2011) (34)
HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element (2018) (33)
ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. (2018) (32)
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1 (2021) (31)
Use of 2'-spirocyclic ethers in HCV nucleoside design. (2014) (31)
High throughput on-bead monitoring of solid phase reactions by Diffuse Reflectance Infrared Fourier Transform Spectroscopy (DRIFTS) (1997) (27)
Adenosine deaminase-like protein 1 (ADAL1): characterization and substrate specificity in the hydrolysis of N(6)- or O(6)-substituted purine or 2-aminopurine nucleoside monophosphates. (2011) (26)
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit (2021) (26)
Analysis of the interaction of haloenol lactone suicide substrates with .alpha.-chymotrypsin using computer graphics and molecular mechanics (1985) (26)
Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies. (1999) (25)
Synthesis of five-membered halo enol lactone analogs of .alpha.-amino acids: potential protease suicide substrates (1983) (24)
3-(Acylamido)-4-phenyl-6(E)-(iodomethylidene)tetrahydro-2-pyranones. Synthesis of novel amino acid analogues (1985) (22)
Generation of oligosaccharide and glycoconjugate libraries for drug discovery (1996) (21)
Inhibition of HBV replication by N‐hydroxyisoquinolinedione and N‐hydroxypyridinedione ribonuclease H inhibitors (2019) (21)
Enol lactone inhibitors of serine proteases. The effect of regiochemistry on the inactivation behavior of phenyl-substituted (halomethylene)tetra- and -dihydrofuranones and (halomethylene)tetrahydropyranones toward alpha-chymotrypsin: stable acyl enzyme intermediate. (1986) (21)
An Empirical Process for the Design of High-Throughput Screening Deck Filters. (2006) (20)
Solid phase synthesis of novel pyrrolidinedione analogs as potent HIV-1 integrase inhibitors. (2010) (20)
Carbohydrate-based combinatorial libraries (1997) (20)
Synthetic and Structure-Activity Studies on Acid-Substituted 2- Arylphenols: Discovery of 2-(2-Propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)- 5-hydroxyphenoxy)propoxy)phenoxy)benzoic Acid, a High-Affinity Leukotriene B4 Receptor Antagonist. (1996) (19)
Metabolic Activation of the Anti-Hepatitis C Virus Nucleotide Prodrug PSI-352938 (2012) (18)
Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils. (1992) (17)
β-D-2'-α-F-2'-β-C-Methyl-6-O-substituted 3',5'-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study. (2012) (16)
Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production. (1991) (15)
Phosphorus-Containing Inhibitors of HMG-CoA Reductase. Part 1. 4-((2- Arylethyl)hydroxyphosphinyl)-3-hydroxybutanoic Acids: A New Class of Cell-Selective Inhibitors of Cholesterol Biosynthesis. (1991) (15)
Synthesis of phenyl 1-thioglycopyranosiduronic acids using a sonicated jones oxidation (1998) (14)
Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model. (2019) (13)
Intestinal Transport of Gentamicin with a Novel, Glycosteroid Drug Transport Agent (1998) (13)
A 2′-Deoxy-2′-Fluoro-2′-C-Methyl Uridine Cyclopentyl Carbocyclic Analog and Its Phosphoramidate Prodrug as Inhibitors of HCV NS5B Polymerase (2012) (13)
Synthesis and anti-HCV activity of 3',4'-oxetane nucleosides. (2010) (12)
Synthesis and biological evaluation of analogues of bacterial lipid I. (2000) (12)
Phosphoramidate Prodrugs of (−)-β-D-(2R,4R)-dioxolane-thymine (DOT) as Potent Anti-HIV Agents (2012) (11)
Expeditious route to F unit building block of moenomycin A (1999) (11)
1034 COMBINATION OF TWO COMPLEMENTARY NUCLEOTIDE ANALOGUES PSI-7977 AND PSI-938 EFFECTIVELY CLEARS WILD TYPE AND NS5B:S282T HCV REPLICONS – COMPARISON WITH COMBINATIONS OF OTHER ANTIVIRAL COMPOUNDS (2010) (11)
Novel carbohydrate scaffolds. Assembly of a uridine–mannose scaffold based on tunicamycin (2000) (11)
3-Azido-3-deoxy-glycopyranoside derivatives as scaffolds for the synthesis of carbohydrate-based universal pharmacophore mapping libraries. (2003) (11)
Solid-phase synthesis and anti-infective activity of a combinatorial library based on the natural product anisomycin. (2005) (11)
Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. (1993) (10)
The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class. (1997) (10)
The efficient synthesis of a bis-glycosylated steroid drug transport reagent: Methyl 3-β-amino-7α, 12α-di(1′α-glucosyl)-5β-cholate (TC002) (1997) (10)
Synthesis OF differentially protected phenyl d-thioglucopyranosides and 1-phenyl d-thioglucopyranosiduronic acids (1998) (10)
Enter Sofosbuvir: The Path to Curing HCV (2016) (8)
Molecular and Structural Basis for the Roles of Hepatitis C Virus Polymerase NS5B Amino Acids 15, 223, and 321 in Viral Replication and Drug Resistance (2014) (8)
Durable inhibition of hepatitis B virus replication and antigenemia using a subcutaneously administered siRNA agent in preclinical models (2018) (8)
FRI-184-Function and drug combination studies in cell culture models for AB-729, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infection (2019) (8)
Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer (2018) (8)
Solid phase synthesis of peptidoglycan monomers for the generation of a combinatorial library (1996) (8)
o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. (1993) (8)
3-(Acylamido)-4-phenyl-6(E)-(iodomethylene)tetrahydro-2-pyranones. Synthesis of novel amino acid analogs (1985) (7)
Potent, Rationally Designed Inhibitors of Squalene Synthase (1992) (7)
Attachment of unreactive amines to the solid support: synthesis of phenyl-substituted anilines, 2-aminopyridines, and 2-aminopyrimidines. (2003) (7)
Chapter 11:2′-F-2′-C-Methyl Nucleosides and Nucleotides for the Treatment of Hepatitis C Virus: from Discovery to the Clinic (2010) (7)
Chapter Fifteen - Nucleosides and Nucleotides for the Treatment of Viral Diseases (2014) (6)
-alkoxyphenol leukotriene B4 receptor antagonists: effect of a chroman carboxylic acid. (1992) (6)
Carbohydrate-Based Small-Molecule Scaffolds for the Construction of Universal Pharmacophore Mapping Libraries. (1998) (6)
alkoxyphenol leukotriene B4 receptor antagonists (1992) (6)
In Search of Novel Antibiotics Using a Natural Product Template Approach (2008) (6)
The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA (2020) (5)
HCV: The Journey from Discovery to a Cure: Volume I (2019) (5)
Solid phase synthesis of 1,5-disubstituted pyrazole-4-hydroxamic acids and pyrazole-4-carboxamides via direct amidation of β-ketoesters (2012) (5)
ANALYSIS OF THE INTERACTION OF HALOENOL LACTONE SUICIDE SUBSTRATES WITH α-CHYMOTRYPSIN USING COMPUTER GRAPHICS AND MOLECULAR MECHANICS (1985) (5)
Sofosbuvir: The Discovery of a Curative Therapy for the Treatment of Hepatitis C Virus (2016) (4)
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) (2022) (4)
Discovery and optimization of (R)-prolinol-derived agonists of the Growth Hormone Secretagogue receptor (GHSR). (2008) (4)
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein (2021) (4)
The Discovery of Sofosbuvir: A Liver-Targeted Nucleotide Prodrug for the Treatment and Cure of HCV (2019) (4)
Synthesis of Stable Isotope Labeled Analogs of the Anti-Hepatitis C Virus Nucleotide Prodrugs PSI-7977 and PSI-352938 (2011) (4)
Recent developments in solid- and solution-phase methods for generating carbohydrate libraries. (1999) (4)
2-alkyl-4-ethyl-5-[6-methyl-6-(2H-tetrazol-5-yl)heptyloxy]phenol leukotriene B4 receptor antagonists (1995) (3)
Harvoni: A Combination Therapy for Curing HCV (2017) (3)
Chapter 12. Novel Approaches to Anti-Inflammatory Agents as Therapeutics for Pulmonary Disease (1993) (3)
Hepatitis C Virus-From Discovery to Cure: The 2016 Lasker-DeBakey Clinical Medical Research Award. (2016) (3)
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells (2022) (3)
Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNA (2021) (3)
The Efficient Synthesis of a Bis-glycosylated Steroid Drug Transport Reagent: Methyl 3-β-Amino-7α-, 12α-Di(1′α-glucosyl)-5β-cholate (TC002). (1998) (2)
Rapid differentiation of nucleotide phosphoramidate diastereomers by electrospray ionization tandem mass spectrometry. (2012) (2)
Discovery and Development of PSI‐6130/RG7128 (2011) (2)
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B (2022) (2)
A liquid chromatography-tandem mass spectrometry method for the quantitative determination of diastereomers of a phosphoramidate nucleotide prodrug (PSI-7851) in human plasma. (2012) (2)
Publisher Correction: Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients (2020) (2)
QSAR study of ortho-phenylphenol leukotriene B4 receptor antagonists (1994) (2)
Diastereofacial selection in the 1,2-addition of MeMgX and McLi to 4-oxo sugar:Efficient synthesis of 4-C-methyl-l-S-β-D-gluco- and galactopyranoside building blocks of moenomycin (1999) (2)
Aerosolized LTB4 produces delayed onset increases in pulmonary gas trapping. (1996) (2)
Hepatitis B virus core protein variants observed in a first-in-human placebo-controlled study of a core protein inhibitor (2020) (2)
Host RNA quality control as a hepatitis B antiviral target. (2020) (2)
Discovery of a β-D-2 0-Deoxy-2 0-r-fluoro-2 0-β-C-methyluridine Nucleotide Prodrug ( PSI-7977 ) for the Treatment of Hepatitis C Virus (2010) (2)
Solid-phase synthesis of a library based on biphenyl-containing trypsin-like serine protease inhibitors. (2009) (2)
Acid unit modifications of 1,2,4,5-substituted hydroxyacetophenones and the effect on in vitro and in vivo LTB4 receptor antagonism (1993) (2)
Pulmonary responses of the guinea pig to inhaled A23187: A brief review (1992) (1)
Use of PLA2 inhibitors in the treatment of Alzheimer's disease (1996) (1)
CHAPTER 12:Prodrugs in the Treatment of Viral Diseases (2013) (1)
In Vitro and in Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly (2016) (1)
Crystalline form of sofosbuvir (2010) (1)
Improving drug discovery output--starting with the early discovery enterprise. (2004) (1)
Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients (2022) (1)
Chemical Strategies for Introducing Carbohydrate Molecular Diversity into the Drug Discovery Process (1997) (1)
HCV: The Journey from Discovery to a Cure: Volume II (2019) (1)
Purine nucleoside synthesis (2009) (1)
Enol Lactone Inhibitors of Serine Proteases. The Effect of Regiochemistry on the Inactivation Behavior of Pheny1-Substituted (Halomethylene)tetra- und -dihydrofuranones and (Halomethylene)tetrahydropyranones Toward α-Chymotrypsin: Sta (1986) (1)
Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients (2022) (1)
The Generation of Carbohydrate‐based Combinatorial Libraries for Drug Discovery (2010) (1)
Pregenomic RNA Launch Hepatitis B Virus Replication System Facilitates the Mechanistic Study of Antiviral Agents and Drug-Resistant Variants on Covalently Closed Circular DNA Synthesis (2022) (1)
Diastereofacial Selection in the 1,2-Addition of MeMgX and MeLi to 4-Oxo Sugar: Efficient Synthesis of 4-C-Methyl-1-S-β-D-gluco- and -galactopyranoside Building Blocks of Moenomycin. (1999) (0)
Review Nucleotide prodrugs for HCV therapy (2011) (0)
SYNTHESIS OF FIVE-MEMBERED HALO ENOL LACTONE ANALOGS OF α-AMINO ACIDS: POTENTIAL PROTEASE SUICIDE SUBSTRATES (1984) (0)
Publisher Correction: Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients (2020) (0)
Expeditious Route to F Unit Building Block of Moenomycin A. (1999) (0)
Herstellungsverfahren fuer n-[(2'r)-2'-deoxy-2'-fluor-2'-methyl-p-phenyl-5' -uridylyl]-l-alanin 1-methylethylester (2010) (0)
Substituted phenylphenol leukotriene antagonists (1992) (0)
Phosphorus-containing HMG-CoA reductase inhibitors, methods for their production, their use and new intermediates (1988) (0)
Correction to Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase. (2017) (0)
Novel Carbohydrate Scaffolds. Assembly of a Uridine—Mannose Scaffold Based on Tunicamycin. (2000) (0)
Stereoselective synthesis of active agents containing phosphorus (2011) (0)
Stereospecific Reductive Methylation via a Radical Cyclization-Desilylation Process. (1987) (0)
Leukotriene antagonistic substituted phenylphenol (1992) (0)
2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus (2011) (0)
Oligosaccharide and Glycoconjugate Solid-Phase Synthesis Technologies for Drug Discovery (1999) (0)
Introduction to the antibiotic and antiviral compounds themed collection. (2022) (0)
Synthesis of Differentially Protected Phenyl D-Thioglucopyranosides and 1-Phenyl D-Thioglucopyranosiduronic Acids. (1998) (0)
Halo Enol Lactones as Enzyme-Activated Irreversible Inhibitors of Alpha-Chymotrypsin: I. The Effect of Lactone Substitution Pattern. Ii. Alpha - Amino-Functionalized Lactones (1984) (0)
Inhibitors hmg-coa reductase, containing phosphorus, new intermediates of these inhibitors and process for their preparation (1988) (0)
(s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate cristallin (2011) (0)
The identification of highly efficacious functionalised tetrahydrocyclopenta[c]pyrroles as inhibitors of HBV viral replication through modulation of HBV capsid assembly. (2022) (0)
Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver (2022) (0)
Process for the preparation of ester N - [(2'R) -2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridilil] -L-alanine 1-methylethyl (2010) (0)
Phosphorus-containing HMG-CoA reductase inhibitors, intermediates and processes for their preparation (1988) (0)
PSI-7851, a Pronucleotide of (cid:1) - D -2 (cid:2) -Deoxy-2 (cid:2) -Fluoro-2 (cid:2) - C -Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication (cid:1) (2010) (0)
Preclinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors. (2022) (0)
Curing Hepatitis C with Direct‐Acting Antiviral Therapy (2021) (0)
Synthesis of Phenyl 1‐Thioglycopyranosiduronic Acids Using a Sonicated Jones Oxidation. (1998) (0)
HBsAg and Immune Competency; is HBsAg a Mere Biomarker or a Therapeutic Target for Chronic Hepatitis B? (2022) (0)
Sofosbuvir: A Breakthrough Curative Therapy for the Treatment of HCV Infection (2015) (0)
Promedicaments de 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate purifie destines au traitement d'infections virales (2009) (0)
Editorial overview: Anti-infectives (2016) (0)
Accessing carbohydrate-based combinatorial libraries through solid phase and solution phase approaches (1999) (0)
Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of (cid:1) - D -2 (cid:2) -Deoxy-2 (cid:2) - (cid:3) -Fluoro-2 (cid:2) - (cid:1) - C -Methylguanosine (cid:1) † (2011) (0)
Leading Edge Stories Enter Sofosbuvir : The Path to Curing HCV (2016) (0)
HCV NS5B Inhibitor PSI-6130 (2010) (0)
Synthesis of PSI-352938 (2011) (0)
Use of PLA 2 inhibitors in the treatment of Alzheimer's disease (1996) (0)
Perspectives on HCV Cure (2019) (0)
Adenosine Deaminase-like Protein 1 (ADAL1) Catalyzes Removal of Different Alkyl Groups from N6- or O6-substituted Purine or 2-Aminopurine Nucleoside Monophosphates (2011) (0)
Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients (2020) (0)

This paper list is powered by the following services:

Other Resources About Michael J. Sofia

en.wikipedia.org

What Schools Are Affiliated With Michael J. Sofia?

Michael J. Sofia is affiliated with the following schools:

Image Attributions

Image Source for Michael J. Sofia